OrthoPediatrics (NASDAQ:KIDS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of OrthoPediatrics (NASDAQ:KIDS - Free Report) from a hold rating to a sell rating in a report issued on Friday morning.

A number of other analysts also recently weighed in on the company. Truist Financial decreased their price objective on OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a report on Friday, April 11th. Lake Street Capital assumed coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They set a "buy" rating and a $37.00 price target on the stock. Stifel Nicolaus cut their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price target on shares of OrthoPediatrics in a research report on Thursday, May 8th. Finally, Piper Sandler cut their price target on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.83.

OrthoPediatrics Trading Up 1.6%

NASDAQ KIDS traded up $0.33 on Friday, reaching $21.19. The company had a trading volume of 241,054 shares, compared to its average volume of 199,453. The firm has a market cap of $514.64 million, a price-to-earnings ratio of -17.23 and a beta of 1.08. OrthoPediatrics has a fifty-two week low of $19.52 and a fifty-two week high of $35.99. The business has a 50 day moving average of $21.66 and a two-hundred day moving average of $23.47. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The company had revenue of $52.41 million during the quarter, compared to analyst estimates of $51.68 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. Analysts forecast that OrthoPediatrics will post -0.93 EPS for the current year.

Insider Buying and Selling at OrthoPediatrics

In other news, CFO Fred Hite sold 6,443 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $160,172.98. Following the transaction, the chief financial officer now owns 207,989 shares of the company's stock, valued at $5,170,606.54. This represents a 3.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $132,006.60. Following the transaction, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. This trade represents a 4.57% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,732 shares of company stock valued at $589,978. 32.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OrthoPediatrics

Institutional investors and hedge funds have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS bought a new position in OrthoPediatrics in the 4th quarter valued at about $79,000. AlphaCentric Advisors LLC bought a new position in OrthoPediatrics in the 4th quarter valued at about $171,000. Wells Fargo & Company MN lifted its position in OrthoPediatrics by 31.1% in the 4th quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock valued at $228,000 after acquiring an additional 2,338 shares in the last quarter. PDT Partners LLC bought a new position in OrthoPediatrics in the 1st quarter valued at about $244,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock valued at $246,000 after acquiring an additional 645 shares in the last quarter. Institutional investors own 69.05% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.